About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AMPH · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Jul 22, 2026Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimi…
NCT07560150 · Pharmacokinetics, Pharmacodynamics
I004, NovoLog
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2/3Completed62Jun 22, 2026Registry ↗
Mar 5, 2026Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimi…
NCT05539872 · Pharmacokinetics, Pharmacodynamics
I004, NovoLog
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2/3Completed69Jan 29, 2023Registry ↗
Mar 30, 2021Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epineph…
NCT04207840 · Pharmacokinetics, Epinephrine
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Au…
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 4Completed28Dec 20, 2019Registry ↗
Sep 25, 2018Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers
NCT01143051 · Asthma
epinephrine inhalation aerosol, epinephrine inhalation aero…
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 1/2Completed24Jun 2010Registry ↗
Jul 31, 2018Evaluation of Efficacy and Safety of E004 in Children With Asthma
NCT01460511 · Asthma
E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 3Completed70Mar 2012Registry ↗
May 16, 2018Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
NCT01025648 · Asthma
E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E0…
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 1/2Terminated9Dec 2009Registry ↗
Jul 25, 2017Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
NCT01188577 · Asthma, Bronchospasm
Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation…
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 1/2Completed23Sep 2010Registry ↗
Jul 2, 2017Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of…
NCT01189396 · Asthma, Bronchospasm
A006, Placebo DPI
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed27Dec 2010Registry ↗
May 19, 2017Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
NCT01581177 · Asthma
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed23Jul 2012Registry ↗
Apr 19, 2017Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
NCT02271334 · Asthma
A006 DPI, A006 DPI
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed22Oct 2014Registry ↗
Apr 19, 2017Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
NCT02210806 · Asthma
A006 DPI, A006 DPI
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed22Sep 2014Registry ↗
Apr 19, 2017Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
NCT01174732 · Asthma, Bronchospasm
albuterol inhalation powder, albuterol inhalation powder
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed26Oct 2010Registry ↗
Feb 13, 2017Safety Study in Adolescent and Adult Patients With Asthma
NCT01476904 · Asthma
Placebo, Primatene Mist
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 3Completed208Apr 2012Registry ↗
Jan 20, 2017Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
NCT01689363 · Allergic Skin Reaction
Hyaluronidase, Histamine
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed253Nov 2012Registry ↗
Mar 17, 2016Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
NCT01737892 · Asthma
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhala…
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 1/2Terminated21Nov 2012Registry ↗
Mar 17, 2016Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
NCT01255709 · Asthma
Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 2Completed24Jan 2011Registry ↗
Mar 11, 2016Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma
NCT01737905 · Asthma
Epinephrine HFA-MDI (E004), Placebo-HFA
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 3Completed28Mar 2013Registry ↗
Mar 11, 2016Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
NCT01357642 · Asthma
Epinephrine inhalation aerosol, Placebo
AMPH
Amphastar Pharmaceuticals, Inc.
Phase 3Completed373Nov 2011Registry ↗

18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:21 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances